Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CBX-12 in Advanced Solid Tumors
NCT05691517Phase 1Recruiting
- Sponsor
- National Cancer Institute
- Start
- Jun 2024
- Primary completion
- Oct 2028
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of alphalex exatecan in solid tumor, sponsored by National Cancer Institute. Primary endpoints: Early Rad51/deoxyribonucleic acid (DNA) damage response (DDR) and Late Rad51/deoxyribonucleic acid (DNA) damage response (DDR). Started Jun 2024; status: recruiting.
02
Drugs
alphalex exatecan
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05691517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05691517.